Skip to content

Abstract A176: Low utilization of the Decipher genomic classifier and oncologic outcomes in African American men with localized prostate cancer: A cancer-disparities analysis

Oct 2026 · Cancer Epidemiology, Biomarkers & Prevention · 0 citations

Abstract

African American men experience disproportionately high prostate cancer (PCa) mortality and are underrepresented in genomic studies. We evaluated real-world Decipher utilization and oncologic outcomes among African American men treated definitively for localized PCa. We retrospectively identified African American men with localized prostate cancer treated with radical prostatectomy (RP) or radiation therapy with or without androgen-deprivation therapy (RT±ADT) across 3 Mayo Clinic sites between 2010 and 2024. Baseline variables included age, prostate-specific antigen (PSA ng/mL), clinical T stage, treatment, Gleason score, and radiographic findings. Biochemical progression was defined as PSA ≥0.2 ng/mL after RP or ≥2 ng/mL above nadir after RT; metastases were determined by imaging. All time-to-event outcomes were measured from diagnosis. Kaplan–Meier methods estimated overall survival (OS), biochemical progression-free survival (bPFS), and metastasis-free survival (MFS) by Decipher status and clinical subgroups, with comparisons using log-rank tests. Multivariable Cox proportional-hazards models were fitted, and the proportional-hazards assumption was assessed using Schoenfeld residuals. Two-sided p<0.05 was considered statistically significant. Among 191 identified patients, 69 underwent RP and 122 received RT±ADT; median follow-up was 62 months. Decipher testing was performed in 12 patients (6.3%), and germline testing in 51 (26.7%). Tested patients had lower-grade disease (Gleason <8 in 92% vs 58%; p=0.03). Four deaths occurred, including 1 among Decipher-tested patients and 3 among untested patients. There were 60 bPFS events (31%) and 34 MFS events (18%). In overall population, there was no statistically significant difference in patients who received decipher testing compared to those who did not in terms of OS (p=0.13), bPFS (p=0.14), or MFS (p=0.22). In exploratory multivariable models, PSA ≥20 ng/mL (aHR 11.4, 95% CI 4.8–27.3), Gleason score ≥8 (aHR 2.40, 95% CI 1.01–5.69), and clinical stage T3–T4 (aHR 2.58, 95% CI 1.15–5.81) was associated with worse MFS, whereas the addition of ADT to RT was associated with improved MFS compared to RT alone (aHR 0.15, 95% CI 0.04–0.50). Moreover, RT±ADT improved bPFS compared to RP (aHR 0.21, 95% CI 0.09–0.47) and patients with PSA ≥20 at baseline were associated with worsened bPFS compared to those who had PSA <20 (aHR 2.33, 95% CI 1.12–4.88). OS data was not mature. The utilization of decipher testing was limited in African American men with localized PCa, suggesting a potential gap in access to precision-oncology tools in this patient population. Testing status was not associated with outcomes, although analyses were limited by the small sample size. Exploratory analyses showed association of clinicopathological charatersitics with MFS and bPFS and can be considered for clinical decision making. Prospective, adequately powered studies are needed to evaluate equitable genomic-testing use and prognostic value in African American men. Kaneez Zahra R. Khakwani, Muhammad Ali Khan, Muhammad Umar Afzal, Ahmed A. Khan, Usama Mumtaz Cheema, Syed Arsalan Ahmed Naqvi, Chueh Hsuan Hsu, Ewan Cobran, Irbaz B. Riaz. Low utilization of the Decipher genomic classifier and oncologic outcomes in African American men with localized prostate cancer: A cancer-disparities analysis [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr A176.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.